: Integrase inhibitor-based antiretroviral therapy (INSTI-ART) can cause weight gain. It is unknown if this is a class effect, with limited data regarding raltegravir. In 37 virologically suppressed adults (36… Click to show full abstract
: Integrase inhibitor-based antiretroviral therapy (INSTI-ART) can cause weight gain. It is unknown if this is a class effect, with limited data regarding raltegravir. In 37 virologically suppressed adults (36 men, mean age 49 years) who switched from tenofovir disoproxil fumarate to raltegravir 400 mg twice daily, mean weight changes from baseline at Weeks 24, 48 and 96 were not significant (maximum 0.8 kg at Week 24; all p≥0.16). Weight gain may not occur with all INSTIs.
Keywords:
raltegravir associated;
tenofovir raltegravir;
raltegravir;
weight gain;
switch tenofovir
Journal Title: AIDS
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: AIDS
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!